chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The patient was not had any history of previous immunization with the Pfizer vaccine. There were no additional vaccines administered on same date of the Pfizer suspect. The patient had no prior vaccines 4 weeks before the Pfizer vaccination, has not had any vaccines within ten years, but is due for a tetanus vaccine. The outcome of myalgia was reported as recovering and all the other events were recovered 28May2021 and unknown for allergies are a little worse. There was product quality complaint (PQC) found.
Classic case of shingles in the right T2-T3 distribution (burning pain with skin sensitivity starting 1 week after receiving the vaccine and on erythematous vesicular rash in the same distribution five days after the pain started).
Ataxia, lost of balance; seen by PMD and neurologist to rule out Guillian-Barre syndrome; progressive neurological problems. Still under neurologist's care.
On 08/12/2022  I experienced difficulty breathing, headache,   fatigue, low grade  fever and cough. I tested positive on the day of my appointment with my doctor on 08/15/2022.  My doctor prescribed me with  albuterol, dexamethasone for 1 week,  and cough medicine  promethazine  as needed. I have  lingering sinus headaches and migraines.
swelling , itching, pain ,redness, hot area. Started Xyzal and Prednisone 5 mgs, Panadol 500 mgs, cold compresses for about 3 days.   then in January 1, started antibiotic Augmentin bid, because it became  worst. Now with redness , hot area, but improving>I am a Doctor.  Moderna Vaccine
fever; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 07May2021 (Batch/Lot number was not reported) as 1single dose for covid-19 immunisation.  The patient medical history was not reported. The patient's concomitant medications were not reported.  The patient experienced fever (non-serious) on 10May2021 with outcome of unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
3 weeks after 1st dose of Moderna Covid-19 vaccine went into atrial fibrillation; This spontaneous case was reported by a consumer and describes the occurrence of ATRIAL FIBRILLATION (3 weeks after 1st dose of Moderna Covid-19 vaccine went into atrial fibrillation) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced ATRIAL FIBRILLATION (3 weeks after 1st dose of Moderna Covid-19 vaccine went into atrial fibrillation) (seriousness criterion medically significant). At the time of the report, ATRIAL FIBRILLATION (3 weeks after 1st dose of Moderna Covid-19 vaccine went into atrial fibrillation) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.   This case was linked to MOD-2021-230057 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
This spontaneous report as received from a pharmacist refers to a 66 year old female patient with unspecified nodular cancer. The patient had no drug reactions/allergies. On 21-OCT-2014 the patient was vaccinated with PNEUMOVAX 23 (lot#, dose, dose# and route unspecified). Almost immediately after the vaccination the patient experienced a "severe injection site reaction accompanied by fever and malaise" on 21-OCT-2014. Pharmacist reported that the injection site was "warm to the touch and swollen with erythema". Pharmacist stated "it looked like cellulitis". Pharmacist referred the patient to her unspecified physician who prescribed an unspecified antibiotic for treatment. Pharmacist reported that the patient came back to the pharmacy "about a week later" and the reaction site was "going down but still present" and the patient still felt malaise. No lab diagnostics were performed. The outcome of the event "cellulitis/ severe injection site reaction accompanied by fever/injection site was warm to the touch and swollen with erythema" was recovering/resolving. The outcome of the event malaise was not recovered. Additional information has been requested.
Headache, sore throat, nausea, emesis, abdominal pain and head congestion.
This spontaneous report as received from a Pharmacist refers to a 69 years old male patient. The patient was vaccinated with ZOSTAVAX (dose, route and lot # were unknown) an unspecified date. No other co-suspects were reported. Concomitant medications included: AMOXICILLIN. On an unknown date the patient developed a rash at the injection site of the ZOSTAVAX. The pharmacist indicated that on an unspecified date the rash resolved. The pharmacist indicated the patient had another rash appear on the side of the neck that did not resolve. The patient sought medical attention at their doctor's office and saw a nurse. It was indicated by the nurse that it wasn't believed to be caused by the ZOSTAVAX. The pharmacist described the adverse effect as an alligator like crust which subsided in the evening but flared during the daytime and worsened when hot water was applied. Additional information is not expected.
Breakthrough case admission after 2 Janssen vaccines Janssen 4/12/21 lot# 042A21A;  Janssen 12/1/21 lot# 2115521A
Case number PHEH2016US026590, is an initial spontaneous report received from a healthcare professional on 11 Oct 2016. This report refers to a female patient of unknown age. Medical history and concomitant medications were not reported. The patient was vaccinated with a single dose of FLUVIRIN (unknown whether seasonal or pandemic influenza vaccine, batch number: not reported) at a dose of 0.5 ml intramuscularly on an unknown date. It was reported that, expired vaccine was given to a patient about a week ago. No adverse event was reported following this administration error. The case was lost to follow up at initial.
swelling of entire lt arm w/heat, induration & erythema, but no pain or tenderness;seen & tx w/DPH & warm compresses;resolved by 29NOV95;
Narrative: Fem bypass 12/4/2019 Taking asa Plavix at time of clot Second Moderna vaccine 3/10; VTE diagnosed 3/29 Hx CVA (2002?) h/o Kidney failure recurrent prostate cancer BMI 32 Patient with many comorbid disease states, but was on Plavix + 81 mg aspirin at time of clot that occurred  within 3 weeks of second Moderna vaccine (same leg had fem bypass Dec 2019)
1 of 5 pts who were vaxed from the same lot# & exp an adverse event;pt recvd vax 9JUN & 9JUN c/o inc pain @ normally painful sites (i.e. knee, hip & lower back);pain was treated w/APAP;recovered;
This spontaneous report was received from a physician, via company representative, and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, concomitant therapies, drug reactions or allergies were not reported. On 11-DEC-2015, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 10 PK, lot # L002310, expiration date 08-JUL-2016, at a dose of 0.5 ml (route and anatomical location of administration were unspecified). The vaccine underwent a total temperature excursion, of 24 hours. The highest recorded temperature was 47 Fahrenheit degrees (8.333333333 Celsius). The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effects were reported. No Product Quality Complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Took Vivotif two days in a row; Spontaneous report received on 27FEB2020.  A female consumer reported that she "took Vivotif two days in a row" (PT: Inappropriate schedule of product administration). She was receiving Vivotif for immunisation. She took the first and second dose of Vivotif on 26FEB2020 and 27FEB2020 respectively. Action taken with Vivotif with respect to the reported event was not applicable. The outcome of the reported event was unknown.  Company Comment: A consumer took first and second doses of Vivotif two days in a row (Inappropriate schedule of product administration) instead of taking it every other day. Considering the nature of the event, the causality of Inappropriate schedule of product administration is assessed as not applicable to Vivotif.; Sender's Comments: A consumer took first and second doses of Vivotif two days in a row (Inappropriate schedule of product administration) instead of taking it every other day. Considering the nature of the event, the causality of Inappropriate schedule of product administration is assessed as not applicable to Vivotif.
Patient received Pfizer COVID -19 vaccine on 4/19/21.  On 4/21/21, patient presented to ED with severe insomnia with agitation,?? acute dystonic reaction, anxiety, and depression. Patient had past medical history pf ADHD, Asthma, GERD, Anxiety, and Depression.  It was not sure if symptom exacerbated due to vaccine, but we will file this incident for record keeping.
Pt. was under two on 12-11-09, and was administered H1N1 intranasally when pt. should have received H1N1 intramuscularly.
Continued pain at injection site for 3 weeks. Ice, heat, TYLENOL.
Left temporal H/A, stabbing that comes and goes. B/P 207/107. Sent to ER
Following vaccine, pt became weak, dizzy and pale. Denies LOC. Escorted back to nurse's office by his mother and school nurse. Pt diaphoretic and pale upon return to office. Atox 3 B/P 92/60, pulse 57. No rash or itching. Denies respiratory difficulties. Pt's color return to normal, skin became warm and dry and B/P improved within 30 minutes. B/P 98/64, pulse 58, regular. Pt returned to class.
Patient tested positive for Covid19 after reviving the Pfizer vaccine EUA 04-01-2021  04-29-2021
Patient presented to emergency room on 5/14/2019 about one week after receiving vaccine after developing a severe headache that started around Noon on 5/14/19. In emergency department was found to have a fever of 102 F. Given fever and headache patient was hospitalized for possible infection and concern for encephalitis/meningitis.
After the second day: Diarrhea and gastric problems, Pain in the injection site, Headache, Erythema with itching in arms, hands, back, thighs and legs. My hands became swollen due to cutaneous eruptions that appeared. The eruptions appeared on the fifth day after the vaccination.
Developed red itchy rash the next day after vaccination. Itchy and warm feel to touch.
Day after vaccine I experienced lower back pain and upper left leg pain.  Two days after the vaccine I observed a rash at the base of my spine, there were four dime sized red, raised hive looking spots.  I also observed throughout the following hours a rash began to track from the base of my spine, down to my left buttock cheek, the side of my upper left thigh, and then the front of my upper left thigh.   I went to Urgent Care and was diagnosed with Shingles.
This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. Patient's pertinent medical history, drug reaction/allergies or concomitant information were not reported. The reporter stated that a dose of GARDASIL 9 was drawn up from the vial and stored for two hours in a plastic syringe. On an unknown date, the patient was vaccinated with a dose of improperly storaged GARDASIL 9 lot # M018810 with expiration date: 28-MAY-2018 (route, dosage schedule, lot # and expiration date were not reported). No adverse event was reported. There was no product quality complaint (PQC) involved. Additional information has been requested.
Decedent had unwitnessed fall out of wheelchair 1/25/21 around 9:43am, denied head strike, pain, discomfort. Around 10:02pm, 1/25/21, decedent noted to have slurred speech and fluctuating HR, transported to Hospital and made cmo.
I started feeling fatigue and a bit of a cough and progressed into flu-like symptoms. On the 6th day I contacted my doctor and was advised to take ADVIL or TYLENOL to keep the fever down and was prescribed a cough suppressant. After about a week or so, the illness broke and I felt better. Even though the initial flu-like symptoms and illness went away I still had issue with my interstitial syssitias and went to doc and had a urinalysis (clear, ruled out bladder infection). No advice given or prescription for syssitias. As of today, this is still an issue.
No adverse events recorded. Administered 0.3ml pfizer booster to 14 year old patient, although only approved for 16+
pt was found cold & unresponsive in crib @ daycare;paramedics noted pt to be mottled & cold;pt ventilated by bag to endotracheal tube;hosp stated no spontaneous HR & poor capillary refill;pupils fixed & dilated;no movement;consistent w/SIDS
(Sorry, couldn't read 2 numbers of the lot number)  I did experience the shot hurting just a little on first and second day, not unlike any other injection I have had in the past. On or around 2/14/21, I started experiencing itching/redness and a lump and warming of the skin which got a little worse in the next few days.  The lump went away first.  I still have a small amount of warmth and redness/itching today 2/20/21.  Yesterday on the 19th, I did have a slight headache (not usual for me) and was a little more tired than normal.  Today, so far, I feel fine other than the small amount of itching and redness.
rash on the buttocks or upper thigh; After about a week the lesions are flat with an ecchymotic appearance; This is a spontaneous report  from a contactable nurse reporting same event under the same suspect product for #4 patients. This is fourth of the patient among four patients. A patient of unspecified age and gender received bnt162b2 (BNT162B2), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history and concomitant medications were not reported.  The patient developed a rash on the buttocks or upper thigh within a few days to a week after getting a Pfizer Covid-19 vaccine. The rash begins with an appearance similar to shingles. After about a week the lesions are flat with an ecchymotic appearance. Outcome of events was unknown.  No follow-up attempts are needed. No further information is expected.
Pt recv vax on 2/4/99; on 2/5/99 pt exp fussiness, fever (99-100), hive-like rash, cough, runny nose
The injectable influenza vaccine was administered by an incorrect route. The flu vaccine should be given intramuscular in the deltoid muscle, but it was given on a much lower spot in the patient's arm.  I took a picture of the injection site, and showed it to the pediatrician's office.  They told me the injection site was incorrect, and the vaccine probably was given subcutaneously.   The pediatrician's office further contacted the county health department, and they suggest the patient to get another dose (the 1st dose was invalid).
Patient reported being fine after vaccination. Patient was standing near me while I was giving other vaccination to family members, patient reported feeling strange to her brother, and then passed out. She hit her face and head on the ground. She awoke for a second, then blacked out for a second time. She came back to, and 911 was called. She busted her lip, and had a small amount of bleeding, but seemed ok otherwise. She was attended to by paramedics, and released without going to the emergency room.
Sleepy; This is a spontaneous report from a non-contactable nurse, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 19Jun2021 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Jun2021, the patient experienced sleepy. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sleepy was not recovered at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient has been having issues with her menstrual  cycle and it nor being regular; This is a spontaneous report from a Pharmacist via medical information team. A non-contactable pharmacist reported for a female patient. A female patient of an unspecified age received second dose of BNT162B2 (Pfizer-BioNTech Covid-19 Vaccine, Formulation: solution for injection, Batch/Lot Number and expiration date was not reported), via an unspecified route of administration on unspecified date on Mar2021 as 2nd dose, single dose for covid-19 immunization. The patient previously received first dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine, Formulation: solution for injection, Batch/Lot Number unspecified, expiration date unspecified), via an unspecified route of administration on an unknown date as 1st dose, single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. On an unknown date after the second dose, Patient has been having issues with her menstrual cycle and it nor being regular. The reporter was wondering if they had any information regarding this occurring with people.Response included that after reviewing the Prescribing Information for Pfizer COVID-19 Vaccine did not find information regarding the vaccine effecting menstrual cycle. As the Prescribing Information does not include all adverse reactions that have been reported or that may occur, please have patient contact her doctor/healthcare provider about what she has been experienced/are experiencing. As Pfizer cannot assess causality with what she is experiencing is associated with the Pfizer COVID-19 Vaccine. The outcome of the event was unknown.  No follow-up attempts are possible. No information about lot/batch number cannot be obtained.
I had the regular arm soreness for a few days after receiving the first dose of the vaccine. Then,  over a week later, a 2-inch red circle has formed around the injection site, my arm is hard and tender within the circle, and the skin is really itchy around the injection site. I'm still having these symptoms today 03/14/21.
Headaches, chills, whole body aches, sensitive skin lasting about 24 hours. period started a week early (during active birth control week)
Patient had been sick for about five days with persistent diarrhea. He was beginning to feel he was becoming dehydrated and would need treatment. Therefore, he went ahead with acute treatment with hydration, his diarrhea had improved. His bradycardia was still present despite the fact that we held his atenolol.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site reaction in a adult patient who received FLULAVAL QUADRIVALENT 2018-2019 season (batch number ZA72G, expiry date May 2019), (batch number 52B5N ?, expiry date May 2019) and (batch number 5FRCW ?, expiry date May 2019) for prophylaxis. On an unknown date, the patient received FLULAVAL QUADRIVALENT 2018-2019 season. On an unknown date, the dose was an unknown dose. On an unknown date, the dose was an unknown dose. On an unknown date, less than a year after receiving FLULAVAL QUADRIVALENT 2018-2019 season, the patient experienced injection site reaction. On an unknown date, the outcome of the injection site reaction was unknown. It was unknown if the reporter considered the injection site reaction to be related to FLULAVAL QUADRIVALENT 2018-2019 season. Additional details were provided as follows: The age at vaccination was not reported. The healthcare professional stated, an employee experienced a rather severe site reaction following administration of FLULAVAL. The healthcare professional did not have any additional information regarding the patients involved or the reaction. The reporter provided 3 lot numbers but unsure which ones might have been used 52B5N, 5FRCW, and ZA72G with expiration date of May 2019. The healthcare professional suggested she will gather additional information and requested to be contacted at a later time by Safety Department. The reported batch number 52B5N and 5FRCW for FLULAVAL QUADRIVALENT 2018-2019 season does not exist in sales database. This case has been linked with case US2018182650, reported by the same reporter.
Threw up within 45 minutes of Vivotif administration; A spontaneous report was received from a pharmacy intern on 15MAY2023 regarding a patient of unknown age and gender who threw up within 45 minutes of Vivotif (typhoid vaccine live oral Ty21A; lot number: unknown) administration (PT: Vomiting) for immunisation.  The patient's medical history, concomitant medications, or known allergies were not reported.  On an unknown date, the patient received a dose of Vivotif and within 45 minutes of administration, the patient threw up.   The outcome of the reported event was unknown, at the time of this report.  The action taken with Vivotif with respect to the reported event was unknown.  No additional information was reported.  Company comment: A patient took Vivotif for immunisation and it was reported that the patient threw up within 45 minutes of Vivotif (vomiting). Considering the case information, the role of Vivotif cannot be ruled out, and the causality of vomiting is assessed as possible. The case is considered non serious as per medical assessment.; Sender's Comments: A patient took Vivotif for immunisation and it was reported that the patient threw up within 45 minutes of Vivotif (vomiting). Considering the case information, the role of Vivotif cannot be ruled out, and the causality of vomiting is assessed as possible. The case is considered non serious as per medical assessment.
bilateral knee pain and shivers, no fever 6 to 8 hours after inject.  Still present after fitfull sleep and malaise now Well done IM, no pain untill hours later. Shivers, nausea.
Within one hour after leaving office, sx began: tightness in throat, numb lips, anxiety. Because of prior Td reaction, kept in office x 20 min with no reaction. Took ibuprofen and BENADRYL after leaving office and nurse at office monitored. Pt. returned to desk. At 11 PM 7/15/10, sx returned and pt took self to ER - given steroid, ibuprofen and BENADRYL. Pt. has fully recovered.
(First day) swelling, redness, and soreness 4" diam around shot; upset stomach, loss of appetite; general fatique; fever and related whole body muscle aches; related chills and sweating - used aspirin 4 times to cover fever and muscle aches. (Second day) Shot area the same, fever and all came on later in the day, used aspirin twice during the night.  (Third day) Shot area the same - pain interferes with sleep, complete exhaustion, loss of appetite, fever doesn't seem so bad, so there's hope for recovery.  But I seem to fall into the 1% that develop fever, muscle aches, and severe local reactions.
One week after receiving the shot, my autoimmune disease flared up after a long time of being dormant. I have an inflammatory condition that causes mild to severe lower back pain. Other side effects include fatigue, constipation, bloating, and pain in other joints such as knees or hips. My flares can last weeks or months. I think people should know that the vaccine can cause a disease flare up.